| Tasaduq N Fazili, MD | |
|
2001 Crystal Spring Ave Sw Ste 301, Roanoke, VA 24014-2465 | |
| (540) 981-7715 | |
| Not Available |
| Full Name | Tasaduq N Fazili |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 30 Years |
| Location | 2001 Crystal Spring Ave Sw Ste 301, Roanoke, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548215171 | NPI | - | NPPES |
| 03361800 | Medicaid | NY | |
| P01227409 | Other | NY | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 261497 (New York) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | 0101267456 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion Medical Center | Roanoke, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carilion Medical Center | 9830096585 | 758 |
News Archive
Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors.
AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
Researchers at Brigham Young University and the Johns Hopkins School of Medicine have discovered a human cell "reservoir," called follicular dendritic cells, that allows HIV to stay in an infectious state and not respond to antiretroviral drugs, the Deseret Morning News reports.
› Verified 8 days ago
| Entity Name | Carilion Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206370 PECOS PAC ID: 5890607253 Enrollment ID: O20031106000273 |
News Archive
Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors.
AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
Researchers at Brigham Young University and the Johns Hopkins School of Medicine have discovered a human cell "reservoir," called follicular dendritic cells, that allows HIV to stay in an infectious state and not respond to antiretroviral drugs, the Deseret Morning News reports.
› Verified 8 days ago
| Entity Name | Carilion Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730123472 PECOS PAC ID: 9830096585 Enrollment ID: O20040107000472 |
News Archive
Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors.
AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
Researchers at Brigham Young University and the Johns Hopkins School of Medicine have discovered a human cell "reservoir," called follicular dendritic cells, that allows HIV to stay in an infectious state and not respond to antiretroviral drugs, the Deseret Morning News reports.
› Verified 8 days ago
| Entity Name | Carilion Giles Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194718304 PECOS PAC ID: 3678670221 Enrollment ID: O20070516000487 |
News Archive
Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors.
AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
Researchers at Brigham Young University and the Johns Hopkins School of Medicine have discovered a human cell "reservoir," called follicular dendritic cells, that allows HIV to stay in an infectious state and not respond to antiretroviral drugs, the Deseret Morning News reports.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tasaduq N Fazili, MD 2001 Crystal Spring Ave Sw Ste 301, Roanoke, VA 24014-2465 Ph: (540) 981-7715 | Tasaduq N Fazili, MD 2001 Crystal Spring Ave Sw Ste 301, Roanoke, VA 24014-2465 Ph: (540) 981-7715 |
News Archive
Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors.
AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
Researchers at Brigham Young University and the Johns Hopkins School of Medicine have discovered a human cell "reservoir," called follicular dendritic cells, that allows HIV to stay in an infectious state and not respond to antiretroviral drugs, the Deseret Morning News reports.
› Verified 8 days ago
Dr. Jed David Gonzalo, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3 Riverside Cir, Roanoke, VA 24016 Phone: 540-224-5170 | |
Dr. Adel M Salama, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1111b S Jefferson St, Roanoke, VA 24016 Phone: 540-342-1007 Fax: 540-345-4643 | |
Dr. Daniel Frank Pauly, , M.D., PH.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2001 Crystal Spring Ave Sw Ste 203, Roanoke, VA 24014 Phone: 540-982-8204 | |
Joshua Gabriel Gazo, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1906 Belleview Ave Se, Roanoke, VA 24014 Phone: 540-981-7000 | |
Joseph L. Austin, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 127 Mcclanahan St Sw, Suite 300, Roanoke, VA 24014 Phone: 540-982-8204 Fax: 540-224-1059 | |
Ali M Yahya, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2213 Stanley Ave Se, Roanoke, VA 24014 Phone: 571-338-9463 | |
Umar Sofi, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2001 Crystal Spring Ave Sw Ste 300, Roanoke, VA 24014 Phone: 540-985-8505 Fax: 540-344-3313 |